Metabolic and Cardiovascular Benefits and Risks of EMD386088-A 5-HT Receptor Partial Agonist and Dopamine Transporter Inhibitor

Overview

Journal Front Neurosci

Date 2017 Feb 24

PMID 28228713

Citations 12

Authors

Magdalena Kotanska

Joanna Sniecikowska

Magdalena Jastrzebska-Wiesek

Marcin Kolaczkowski

Karolina Pytka

Affiliations

Soon will be listed here.

Abstract

Since 5-HT receptors play role in controlling feeding and satiety and dopamine is essential for normal feeding behavior, we evaluated the ability of EMD 386088-5-HT receptor partial agonist and dopamine transporter inhibitor-to reduce body weight in obese rats, as well as its anorectic properties (calorie intake reduction) in rat model of excessive eating and the influence on metabolism (plasma glucose and glycerol levels). We also determined the effect of the studied compound on pica behavior in rats and its influence on blood pressure after single administration. EMD 386088 reduced body weight in obese rats fed high-fat diet and decreased calorie intake in both models applied (rat model of obesity and of excessive eating). In both models EMD 386088 regulated plasma glucose and increased plasma glycerol levels. The latter proves that the compound reduced body fat. We think that it might have increased lipolysis, but this requires further studies. The reduction in glucose levels is the first symptom of metabolic disorders compensation. EMD 386088 did not cause pica behavior in rats but increased blood pressure after single administration. We think that partial 5-HT agonists might have potential in the treatment of obesity. Thus, EMD 386088 requires extended studies.

Citing Articles

The Effect of KSK-94, a Dual Histamine H and Sigma-2 Receptor Ligand, on Adipose Tissue in a Rat Model of Developing Obesity.

Kotanska M, Zadrozna M, Kubacka M, Mika K, Szczepanska K, Nowak B Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065709 PMC: 11280160. DOI: 10.3390/ph17070858.

Metabolic and cardiovascular benefits and risks of 4-hydroxy guanabenz hydrochloride: α-adrenoceptor and trace amine-associated receptor 1 ligand.

Kotanska M, Marcinkowska M, Kuder K, Walczak M, Bednarski M, Siwek A Pharmacol Rep. 2023; 75(5):1211-1229.

PMID: 37624466 PMC: 10539439. DOI: 10.1007/s43440-023-00518-9.

Selective 5-HT Receptor Ligands (Agonist and Antagonist) Show Different Effects on Antipsychotic Drug-Induced Metabolic Dysfunctions in Rats.

Partyka A, Gorecka K, Gdula-Argasinska J, Wilczynska-Zawal N, Jastrzebska-Wiesek M, Wesolowska A Pharmaceuticals (Basel). 2023; 16(2).

PMID: 37259305 PMC: 9967858. DOI: 10.3390/ph16020154.

KSK-74: Dual Histamine H and Sigma-2 Receptor Ligand with Anti-Obesity Potential.

Mika K, Szafarz M, Zadrozna M, Nowak B, Bednarski M, Szczepanska K Int J Mol Sci. 2022; 23(13).

PMID: 35806019 PMC: 9266460. DOI: 10.3390/ijms23137011.

Histamine H Receptor Ligands-KSK-59 and KSK-73-Reduce Body Weight Gain in a Rat Model of Excessive Eating.

Mika K, Szafarz M, Bednarski M, Latacz G, Sudol S, Handzlik J Pharmaceuticals (Basel). 2021; 14(11).

PMID: 34832862 PMC: 8622623. DOI: 10.3390/ph14111080.

References

Bina K, Cincotta A . Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology. 2000; 71(1):68-78. DOI: 10.1159/000054522. View

Li B, Shao D, Luo Y, Wang P, Liu C, Zhang X . Role of 5-HT3 receptor on food intake in fed and fasted mice. PLoS One. 2015; 10(3):e0121473. PMC: 4366218. DOI: 10.1371/journal.pone.0121473. View

Jastrzebska-Wiesek M, Siwek A, Partyka A, Antkiewicz-Michaluk L, Michaluk J, Romanska I . Study of a mechanism responsible for potential antidepressant activity of EMD 386088, a 5-HT6 partial agonist in rats. Naunyn Schmiedebergs Arch Pharmacol. 2016; 389(8):839-49. PMC: 4939156. DOI: 10.1007/s00210-016-1245-3. View

Sargent B, Henderson A . Targeting 5-HT receptors for the treatment of obesity. Curr Opin Pharmacol. 2011; 11(1):52-8. DOI: 10.1016/j.coph.2011.01.005. View

Cunningham J, Wiviott S . Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit. Clin Cardiol. 2014; 37(11):693-9. PMC: 6649490. DOI: 10.1002/clc.22304. View

Stice E, Spoor S, Bohon C, Veldhuizen M, Small D . Relation of reward from food intake and anticipated food intake to obesity: a functional magnetic resonance imaging study. J Abnorm Psychol. 2008; 117(4):924-35. PMC: 2681092. DOI: 10.1037/a0013600. View

Karila D, Freret T, Bouet V, Boulouard M, Dallemagne P, Rochais C . Therapeutic Potential of 5-HT6 Receptor Agonists. J Med Chem. 2015; 58(20):7901-12. DOI: 10.1021/acs.jmedchem.5b00179. View

Stice E, Yokum S, Blum K, Bohon C . Weight gain is associated with reduced striatal response to palatable food. J Neurosci. 2010; 30(39):13105-9. PMC: 2967483. DOI: 10.1523/JNEUROSCI.2105-10.2010. View

Jastrzebska-Wiesek M, Siwek A, Partyka A, Szewczyk B, Sowa-Kucma M, Wasik A . Antidepressant-like activity of EMD 386088, a 5-HT6 receptor partial agonist, following systemic acute and chronic administration to rats. Naunyn Schmiedebergs Arch Pharmacol. 2015; 388(10):1079-88. DOI: 10.1007/s00210-015-1141-2. View

10.

Volkow N, Wang G, Fowler J, Molina P, Logan J, Gatley S . Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma. Psychopharmacology (Berl). 2003; 166(3):264-70. DOI: 10.1007/s00213-002-1340-7. View

11.

Wang G, Volkow N, Logan J, Pappas N, Wong C, Zhu W . Brain dopamine and obesity. Lancet. 2001; 357(9253):354-7. DOI: 10.1016/s0140-6736(00)03643-6. View

12.

Fisas A, Codony X, Romero G, Dordal A, Giraldo J, Merce R . Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats. Br J Pharmacol. 2006; 148(7):973-83. PMC: 1751931. DOI: 10.1038/sj.bjp.0706807. View

13.

Jastrzebska-Wiesek M, Siwek A, Kazek G, Nawiesniak B, Partyka A, Marcinkowska M . Partial agonist efficacy of EMD386088, a 5-HT6 receptor ligand, in functional in vitro assays. Pharmacol Rep. 2013; 65(4):998-1005. DOI: 10.1016/s1734-1140(13)71081-8. View

14.

Jastrzebska-Wiesek M, Siwek A, Partyka A, Kubacka M, Mogilski S, Wasik A . Pharmacological evaluation of the anxiolytic-like effects of EMD 386088, a partial 5-HT6 receptor agonist, in the rat elevated plus-maze and Vogel conflict tests. Neuropharmacology. 2014; 85:253-62. DOI: 10.1016/j.neuropharm.2014.05.036. View

15.

Baik J . Dopamine signaling in food addiction: role of dopamine D2 receptors. BMB Rep. 2013; 46(11):519-26. PMC: 4133846. DOI: 10.5483/bmbrep.2013.46.11.207. View

16.

Makowski C, Gwinn K, Hurren K . Naltrexone/bupropion: an investigational combination for weight loss and maintenance. Obes Facts. 2012; 4(6):489-94. PMC: 6444555. DOI: 10.1159/000335352. View

17.

Liu Y, Connoley I, Heal D, Stock M . Pharmacological characterisation of the thermogenic effect of bupropion. Eur J Pharmacol. 2004; 498(1-3):219-25. DOI: 10.1016/j.ejphar.2004.07.004. View

18.

Volkow N, Wang G, Telang F, Fowler J, Thanos P, Logan J . Low dopamine striatal D2 receptors are associated with prefrontal metabolism in obese subjects: possible contributing factors. Neuroimage. 2008; 42(4):1537-43. PMC: 2659013. DOI: 10.1016/j.neuroimage.2008.06.002. View

19.

Reith M, Blough B, Hong W, Jones K, Schmitt K, Baumann M . Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter. Drug Alcohol Depend. 2014; 147:1-19. PMC: 4297708. DOI: 10.1016/j.drugalcdep.2014.12.005. View

20.

Nikiforuk A, Kos T, Wesolowska A . The 5-HT6 receptor agonist EMD 386088 produces antidepressant and anxiolytic effects in rats after intrahippocampal administration. Psychopharmacology (Berl). 2011; 217(3):411-8. DOI: 10.1007/s00213-011-2297-1. View